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Abstract
Background: There are no prospective randomized controlled trials describing the outcome of acute interstitial nephritis
(AIN) treated with steroids, and retrospective studies are limited.
Methods: We identified adult patients with a diagnosis of AIN without glomerular pathology over a 14-year period. Treated
patients all received oral prednisolone and three also recieved IV methylprednisolone. Data were collected retrospectively
on estimated glomerular filtration rate (eGFR), change in eGFR from time of biopsy, dependence on renal replacement ther-
apy (RRT) and mortality, and outcomes were analysed according to the treatment prescribed.
Results: A total of 187 eligible patients with AIN were identified and 158 were treated with steroids. There was no difference
in median eGFR or dependence on RRT at the time of biopsy. Steroid-treated patients had significantly higher eGFR at all
time points post-biopsy up to 24 months, when median eGFR was 43 mL/min in the steroid-treated group and 24 mL/min in
the untreated group (P ¼ 0.01). Fewer patients in the steroid-treated group were dialysis dependent by 6 months (3.2%
versus 20.6%, P ¼ 0.0022) and 24 months (5.1% versus 24.1%, P ¼ 0.0019).
Conclusions: This large retrospective study suggests a benefit of steroids in treatment of AIN with greater improvement in
eGFR and fewer patients progressing to end-stage renal disease.
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Introduction
Acute interstitial nephritis (AIN) is a common cause of acute
kidney injury (AKI). AIN was found in 6% of almost 4000
native renal biopsies performed at our centre between 1998
and 2011. Other large series have shown AIN to be present in
1–3% of biopsies and in those biopsied for AKI, AIN is present
in up to 27% [1–3]. In patients over 60 years of age, AIN has
been shown to be present in around 10% of biopsies [4]. In
several case series AIN was shown to be increasing in inci-
dence, particularly in the elderly, although this may also
be due to increased rates of biopsy and detection in this
group [5–9].
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AIN was classically described as related to infection, and
tuberculosis (TB) remains an important cause in our series [10].
More recently, AIN has typically been described as a drug-
related phenomenon, initially with methicillin and now with a
broad range of medicines including antibiotics and non-
steroidal anti-inflammatory drugs (NSAIDs) [11–13].
Increasingly, proton pump inhibitors (PPIs) are being identified
as a common cause of AIN [14–16]. It has also been reported in
association with inflammatory conditions such as sarcoidosis,
IgG4-related disease and as part of the tubulointerstitial nephri-
tis and uveitis (TINU) syndrome [17–19].
The clinical features of AIN may include those of hypersensi-
tivity in drug-induced cases, with fever, arthralgia, skin rash
and eosinophilia; however, these are not present in all patients.
Urine dipstick may show haematuria or low-grade proteinuria,
but these features may also be absent. Given the lack of reliable
clinical signs, renal biopsy is needed for diagnosis. Biopsy typi-
cally shows an interstitial inflammatory infiltrate composed
mainly of lymphocytes together with plasma cells and macro-
phages. As AIN progresses, interstitial fibrosis and tubular atro-
phy may develop, leading to chronic kidney disease and
sometimes end-stage renal disease (ESRD) [20].
The role of steroids in treatment of AIN remains controver-
sial, with no prospective randomized controlled trials and con-
flicting evidence from retrospective series [6, 7, 21–24]. There
are several small series showing a benefit for steroids when AIN
is due to sarcoidosis [25, 26]. We performed a retrospective anal-
ysis of 187 patients diagnosed with AIN on renal biopsy in our
centre, the largest reported series, with the aim of evaluating
the benefit of steroids in treatment.
Materials and methods
Subjects
All patients with AIN on renal biopsy were identified from our
biopsy database over a 14-year period. The criteria for diagnosis
were the presence of an interstitial inflammatory cell infiltrate
around non-atrophic tubules, with tubulitis in the absence of
ascending bacterial infection. A retrospective analysis of medi-
cal records and biopsy reports was carried out and data col-
lected on age, gender, ethnicity, biopsy features, estimated
glomerular filtration rate (eGFR) and the need for RRT at the
time of biopsy. Drug-induced AIN was only documented if this
was clearly defined in the notes by the clinician responsible and
the drug concerned discontinued. Patients were excluded if
already on maintenance steroids, if there was a co-existing glo-
merulonephritis present on the biopsy, if they had <3 months
follow up or if insufficient clinical information was available.
The MDRD-4 calculation was used for eGFR and for analysis
patients were divided into categories of eGFR >60 mL/min, 30–
60 mL/min, 15–30 mL/min, <15 mL/min and requiring RRT.
Treatment and outcomes
The patients were divided into those treated with steroids and
those not treated. The dose and duration of steroid therapy were
determined by clinician choice and documented when available.
Response to treatment was assessed by both absolute values for
eGFR and change from baseline eGFR. Timepoints 1, 3, 6, 12 and
24 months, and final (last value documented for each patient)
were used for follow up. For 6 and 12 month time points, results
1 month either side were allowed; for 24 months this was
extended to 2 months either side. Dependence on RRT and
mortality data were collected. Patients with documented drug-
induced AIN and those with TB were analysed as subgroups.
Statistics
Data are reported as median values with range unless otherwise
stated. Mann–Whitney U test was used for continuous variables
and chi-squared for the difference in proportions between two
groups. Results are reported as significant when P< 0.05. The
Kaplan–Meier analysis was used to calculate probabilities of
survival. In order to attempt to control for a number of possible
confounding factors, a matched group was identified using vari-
ables that gave a propensity for patients to be treated with ste-
roids or not. Patients in the steroid-untreated group were
matched with a patient in the treated group according to dia-
betic status, category of renal function at the time of presenta-
tion and the closest match for age possible.
Results
Over the 14-year period analysed, 3983 native renal biopsies
were performed in our centre. We identified 238 patients with
AIN; 51 of these were excluded (28 had insufficient clinical
information, 11 with co-existing glomerular pathology, 4
already on maintenance prednisolone and 8 with length of fol-
low up <3 months), leaving 187 patients for analysis. The
median age of the patients at presentation was 52.4 years (range
16.4–87.8 years). In all, 98 patients were males and 89 females.
The median duration of follow up was 39 months (3–164
months). The most common aetiology was drug-induced AIN
(D-AIN); however, its true incidence was probably under-
estimated as aetiology was only documented as drug induced if
there was clear documentation of a putative causative agent
that was promptly discontinued (Figure 1). Patients diagnosed
with AIN caused by TB were treated with quadruple anti-
tuberculous (TB) therapy in addition to steroids if used.
One hundred and fifty-eight patients were treated with ste-
roids and 29 were managed conservatively. Patients receiving
steroids were all treated with oral prednisolone and three
patients received methylprednisolone prior to oral predniso-
lone. Dose and duration of treatment were variable as this was
determined by clinician choice; however, most patients were
prescribed either 40 mg or 60 mg of oral prednisolone daily.
There was wide variation in duration of steroid therapy; 20.8%
were still on steroids at their last appointment and of these 10
patients required steroids for an underlying or unrelated
inflammatory condition. Thirty-two patients (20.2%) were off
steroids by 3 months and the median duration of treatment was
6 months (1 week–5 years).
Fig. 1. Aetiology of AIN in this series. The proportion with D-AIN is probably
underestimated due to strict inclusion criteria.
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The baseline characteristics of the two groups according to
treatment were comparable and are shown in Table 1. The
groups were well matched in terms of age, gender, length of fol-
low up, eGFR at biopsy and dependence on RRT at biopsy,
although there was a greater proportion of patients with diabe-
tes at diagnosis in the group not treated with steroids. Degree of
tubular atrophy was harder to assess as biopsy reports often did
not record this, but where data were available the percentage of
tubular atrophy was similar between groups. There were rela-
tively more patients with the D-AIN in the steroid-treated group
and more with TB in the untreated group.
The steroid-treated group had a significantly higher eGFR at
6, 12 and 24 months and at final follow up, as shown in Figure 2.
In an attempt to control for selection bias, we compared the
group not treated with steroids with a matched group of 29 ste-
roid-treated patients. The patients were matched by category of
eGFR at biopsy, diabetic status and age. Matched steroid-treated
patients had a higher eGFR compared with untreated patients;
however, this was not statistically significant (except for final
follow up), possibly due to the smaller numbers (Figure 2).
The improvement in eGFR from time of biopsy to all time
points was also better in the steroid-treated group, with a
median change in eGFR of 0 mL/min at all-time points in the
untreated group, and of þ10 mL/min by 3 months (P< 0.0001),
þ16 mL/min by 6 months (P< 0.0001) and þ13 mL/min by 24
months (P< 0.0001) in the treated group.
Patients treated with steroids were more likely to maintain
or recover independent renal function; a lower proportion of
patients in the steroid-treated group were dependent on some
form of RRT at 6 months (3.2% versus 20.6%, P¼ 0.0022) and
24 months (5.1% versus 24.1%, P¼ 0.0019). At last follow up, 9.4%
of the steroid-treated patients and 34.4% of the untreated
patients were dependent on RRT (P¼ 0.0011) (Figure 3). Within
the matched steroid-treated group 6.9% of patients were
dependent on RRT at both 6 and 24 months and 13.7% of
patients were dependent on RRT at last follow up (Figure 3).
Despite the large difference in outcome from the group not
treated with steroids (data shown above) this was not statisti-
cally significant. There were also fewer deaths by 3 years in the
steroid-treated group (6.9% versus 27.6%, P¼ 0.0029) (Figure 4).
Drug-induced AIN
Forty-eight of the patients had clearly defined D-AIN. The most
common drugs implicated were antibiotics (n¼ 17, 36.2%),
NSAIDs (n¼ 12, 25.5%) and PPI (n¼ 5, 10%). Relatively more of
these patients were treated with steroids (n¼ 45, 93.8%) com-
pared with the non-drug-induced group (n¼ 113, 81.4%),
although this did not reach statistical significance (P¼ 0.061).
An equal proportion of patients required RRT at presentation in
the drug-induced and non-drug-induced groups (P¼ 1.00).
Table 1. Baseline characteristics of steroid-treated and not treated groups
Steroid treated Not treated
N 158 29
M/F 80/78 18/11
Age (years) 52.2 (16.4–85.3) 53.8 (19.2–87.8)
Length of follow up (months) 39.9 (3–164) 35 (4–121)
Aetiology [n (%)] Drugs 44 (27%), TINU 6 (3.7%),
sarcoid-16 (10%), TB 19
(11.9%), Sjogrens-4 (2.5%)
Drugs 3 (13.8%), sarcoid 1 (3.4%),
TB 6 (20.7%)
Granulomatous TIN [n (%)] 40 (25.3%) 6 (20.7%)
eGFR at biopsy (mL/min) 20.5 (5–110) 25 (5–59)
Median category of renal function at presentation ( mL/min) 15–30 30–60
RRT dependent at presentation [n (%)] 19 (12.0%) 4 (13.8%)
Diabetic at presentation [n (%)] 20 (12.6%) 10 (34.5%)
Tubular atrophy (%) 30 (0–80), n ¼ 115 30 (0–90), n ¼ 27
Values are given as median with range unless otherwise indicated.
Fig. 2. Median eGFR with interquartile range at serial time points following
biopsy and last documented follow up. S0: patients not treated with steroids; S1:
all patients treated with steroids; S1m: matched group of patients treated with
steroids. P-values refer to comparison of S0 and S1 except for last documented
follow up, at which both S0 compared with S1 and S0 compared with S1m were
significant. *P < 0.05.
Fig. 3. Kaplan–Meier curve showing survival with independent renal function in
all patients treated with steroids (S1), matched group of steroid-treated patients
(S1m) and those not treated (S0).
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Of all patients treated with steroids, we compared those
identified as having D-AIN with all other aetiologies. Those with
D-AIN had significantly worse eGFR category at the time of
biopsy but a higher eGFR category at all time points following
biopsy, demonstrating a relatively better response to treatment
(Figure 5).
The baseline characteristics of the drug-induced group
according to treatment were similar, with median age 55.1 years
and 59% of male patients in the steroid-treated group (n¼ 45),
and 52.8 years and 33.3% of male in the untreated group (n¼ 3).
The median length of follow up was 20 months (range 3–150) in
the steroid-treated group and 19 months (12–25) in the
untreated group. Six of the 44 (13.65%) patients treated with ste-
roids required RRT at the time of biopsy and none of the
untreated patients required RRT. Moreover, eGFR in the treated
group was worse at biopsy than in those not treated with ste-
roids [17 mL/min (5–62) versus 38 mL/min (12–51)].
Statistical analysis was not performed due to small numbers
of untreated patients. Due to the worse eGFR at the time of
biopsy, absolute values for eGFR were lower in the steroid-
treated group at 6 months (48 mL/min versus 55 mL/min), but by
12 months the eGFR in the treated group was higher (47 mL/min
versus 42 mL/min). The steroid-treated group showed more
improvement in creatinine from baseline to 6 months than the
untreated group (þ29.5 mL/min versusþ 13 mL/min), baseline
to 12 months (þ21 mL/min versus1 mL/min) and baseline to
last follow up (þ25 mL/min versus 2 mL/min). Of the six
patients requiring RRT at biopsy in the steroid-treated group,
five regained independent renal function. One further treated
patient developed ESRD although he was noted to be non-
adherent with steroid therapy.
AIN related to TB
Twenty-six patients were diagnosed as having TB and treated
with full-dose anti-TB therapy for at least 6 months. Twelve
(46.1%) patients were of Indian ethnicity, four (15.4%) Pakistani,
three (11.5%) other Asian, three (11.5%) African, one (3.8%)
British and three (11.5%) other or unspecified ethnicity. One
patient was already receiving anti-TB therapy at the time of
biopsy, the others all began treatment post-biopsy. Twenty-
three (88.4%) patients had granulomatous interstitial nephritis.
No patients had evidence of acid fast bacilli on renal biopsy and
diagnosis of TB was made on the basis of the clinical findings
and other investigations. Twenty of these patients were treated
with steroids and six were not. Eight of the steroid-treated
patients and four of the untreated patients were male. The
median age was 38.4 years in the steroid-treated group and 55.0
years in the untreated group. eGFR at the time of biopsy was
25 mL/min and 19 mL/min in steroid-treated and untreated
groups, respectively, and two patients in each group were
dependent on dialysis at time of biopsy.
Statistical analysis was not performed due to the small num-
bers, but patients treated with steroids in addition to anti-TB
therapy had higher eGFR than the untreated patients at 1
month (28.5 mL/min versus 21.5 mL/min), 3 months (31.0 mL/
min versus 20.0 mL/min), 6 months (27.0 mL/min versus
17.5 mL/min), 12 months (27.0 mL/min versus 17.0 mL/min) and
24 months (26.0 mL/min versus 19.5 mL/min). The improvement
in eGFR from the time of biopsy to all time points was also bet-
ter in the steroid-treated group, with a greater median change
in eGFR at 6 months (þ10.5 mL/min versus 0.5 mL/min) and
12 months (þ7.0 mL/min versusþ3.0 mL/min). A lower proportion
of the steroid-treated patients were dependent on dialysis at
6 months (5% versus 33.3%) and 24 months (10% versus 33.3%).
Discussion
AIN is a common cause of AKI, possibly with increasing incidence
over recent years [8, 27]. D-AIN is the most common aetiology,
but there is a broad range of other causes [6].
The role for steroid therapy remains controversial, with no
prospective trials. There is conflicting evidence from retrospec-
tive series, with some studies suggesting a benefit for steroids,
with faster and greater recovery of renal function [12, 22],
whereas other studies have showed no benefit of steroid treat-
ment [5, 7, 24]. The outcomes of recent published series are
summarized in Table 2. In this study, we report a large retro-
spective series with a long median follow up (39 months). We
show that steroids lead to improvement in eGFR and fewer
patients requiring RRT. There was also improved survival of
patients treated with steroids, perhaps because fewer of them
developed ESRD. When we attempted to control for selection
bias by comparing a matched group of steroid-treated patients
with those not treated with steroids there was a trend towards
greater improvement in eGFR and RRT-free survival. These
Fig. 4. Kaplan–Meier curve showing patient survival in all patients treated with
steroids (S1), matched group of steroid-treated patients (S1m) and those not
treated (S0).
Fig. 5. Category of eGFR in steroid-treated patients with D-AIN and those treated
but with another cause for AIN.
236 | M. Prendecki et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/ckj/article-abstract/10/2/233/2738785 by U
niversity C
ollege London user on 15 January 2019
results were not statistically significant, possibly due to small
group size.
Gonzalez et al. [22] described a benefit from steroid treat-
ment. They reported 61 patients with D-AIN; the most common
drugs implicated were antibiotics. The 52 patients who were
treated with steroids showed greater improvement in final
serum creatinine and fewer patients requiring RRT. The authors
also demonstrated that time to starting steroid treatment was
important; those who completely recovered renal function
started steroids at an earlier time point than those who had
incomplete recovery. A more recent series by Raza et al. [28]
reports 49 patients with AIN, 37 of whom were treated with ste-
roids. They report a greater improvement in eGFR in patients
treated with steroids; mean improvement in eGFR was 3.4-fold
in the steroid-treated group compared with 2.0-fold in the
untreated group.
The series reported by Clarkson et al. [24] showed no benefit
for steroid treatment. They included complete data on 42
patients, 26 treated with steroids. The most common aetiology
was D-AIN in 90% of cases. There was no difference in serum
creatinine between the two groups at 1, 6 or 12 months.
However, patients who developed ESRD were excluded from
this analysis (7% of all patients). Valluri et al. [7] reported no sig-
nificant difference in serum creatinine in steroid-treated and
untreated patients with D-AIN. Steroid-treated patients had
more severe AKI at the time of biopsy, suggesting greater
improvement in renal function in these patients compared with
those not treated. The series reported by Muriithi et al. [5] also
showed no improvement in rates of renal recovery when
patients with D-AIN were treated with steroids compared with
those untreated. Again, the patients treated with steroids had
lower baseline eGFR.
There was a lower incidence of D-AIN in our study than in
other recent published series. This is most likely due to our
stringent definition for inclusion in this group and the fact that
cases were identified retrospectively from a biopsy database. It
is likely that a significant proportion of the patients with an
unknown cause for their AIN actually had D-AIN. When we ana-
lysed the subgroup of patients with D-AIN we again showed a
benefit for steroid treatment, with greater improvement in eGFR
in those treated with steroids compared with those not treated
(although numbers were small). When steroid-treated patients
Table 2. Summary and outcome of larger published series of AIN
Reference Year Cases Aetiology Treatment Severity of renal
dysfunction
Proportion
steroid
treated
Outcome
Clarkson
et al. [24]
2004 60 92% drug
induced
Methylprednisolone
500 mg IV 2-4 days,
oral prednisolone
0.75 mg/kg tapered
over 3–6 weeks
58% RRT dependent,
median peak
creatinine 670 lmol/L
60% No difference in serum
creatinine at 1 year
Gonzalez
et al. [22]
2008 61 100% drug
induced
Methylprednisolone
250–500 mg IV for 3–4
days, oral predniso-
lone 1 mg/kg tapered
over 8–12 weeks
23% RRT dependent,
mean peak creatinine
504 lmol/L
85% Higher serum creatinine at
last follow up in those
not steroid treated
(327 lmol/L versus
185 lmol/L), more
patients RRT dependent
(44.4% versus 3.8%)
Raza
et al. [28]
2012 49 67% drug
induced
Oral prednisolone 1 mg/
kg to maximum
60 mg/day
22.4% RRT dependent,
mean creatinine
548 lmol/L
75% Greater improvement in
creatinine in steroid-
treated patients (3.4-fold
versus 2.1-fold)
Muriithi
et al. [5]
2014 133 70% drug
induced
21% received IV methyl-
prednisolone initially,
median starting dose
of oral prednisolone
60 mg for median 7.5
weeks
22% RRT dependent,
median peak
creatinine 335 lmol/L
(24% RRT and peak
creatinine 380 lmol/L
in D-AIN group)
86% (87% in
D-AIN
group)
Within D-AIN group, no dif-
ference in recovery of
renal function within the
first 6 months in steroid-
treated group
Valluri
et al. [7]
2015 171 73% drug
induced
Prednisolone dose not
stated. Median dura-
tion of treatment 3
months
19% RRT dependent,
median creatinine
327 lmol/L at time of
biopsy
63% (59% in
D-AIN
group)
Within D-AIN group, no dif-
ference in median creati-
nine at 1, 3 or 6 months.
No difference in propor-
tion of patients experi-
encing complete renal
recovery (48% of steroid
treated, 41% of steroid
untreated. More severe
AKI in those treated with
steroids, median creati-
nine at biopsy 356 lmol/L
compared to 280 lmol/L
in those not treated)
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with D-AIN were compared with those treated, but with any
other aetiology, they had a higher eGFR at all time points post-
biopsy, despite having a lower eGFR at thetime of biopsy, sug-
gesting a particular benefit of steroids in D-AIN.
There also seems to be a benefit for steroids in patients
with AIN related to TB. The incidence of TB in our study was
high, reflecting the high incidence of TB in our catchment area.
London as a whole contributed 39% of the TB notifications in
the UK in 2014; the highest rates of TB in London were within
North West London; and of the top five local authorities for TB
notification rates three are served by our referring hospitals
[29]. Steroid-treated patients had a higher eGFR at all time
points post-biopsy and a lower proportion of steroid-treated
patients became dependent on RRT. Our patients with TB gen-
erally had worse outcomes when compared with patients with
other causes for AIN. When the groups were compared (includ-
ing both steroid-treated and untreated patients) there was a
smaller median improvement in eGFR in the group with TB
compared with other causes. The relatively poor prognosis of
TB-related AIN has been described in other case series [30]. The
mechanism by which TB causes a granulomatous interstitial
nephritis, generally without evidence of acid fast bacilli on
biopsy, remains unknown [31]. We would suggest that patients
with AIN due to TB are treated with steroids in addition to anti-
TB therapy.
Patients in our series were treated with higher total doses of
steroids than in the Gonzalez series [22], which also showed a
benefit of treatment. In a small number of patients, a rise in cre-
atinine following rapid weaning of steroids prompted re-biopsy
and re-introduction of steroids. We did not see a significant
number of complications despite a more prolonged steroid
course. Of the 171 patients for whom data were available, only
eight patients (4.7%) were documented to have developed diabe-
tes. Of these eight, two patients required chronic steroid treat-
ment for other conditions and three of the eight had steroid
courses that were of 4 months duration or less. All were aged 55
years or older at the time of biopsy.
There are several limitations to our study; in particular
this is a retrospective series with some missing data. In addi-
tion, multiple clinicians at our centre treated patients with
AIN with no defined protocol for steroid use, due to the lack
of evidence. Decision to treat with steroids or not was down
to clinician choice; however, propensity analysis identified
that diabetic status, baseline renal function and age (non-sig-
nificantly) correlated with whether or not patients received
steroids. We therefore report a heterogeneous group of
patients with considerable variation in steroid dose and dura-
tion. There was also variation in time to introduction of ste-
roids, from within hours of biopsy to a few weeks. More
patients were treated with steroids than not, which makes
statistical analysis of subgroups difficult due to small num-
bers in the non-steroid-treated groups.
Despite the limitations, the outcome of this large series of
patients with long-term follow up showing improvement in
renal function, and some patients becoming dialysis independ-
ent during follow up, provides further evidence for the benefit
of steroid therapy in AIN. Based on our results, we would sug-
gest the use of oral prednisolone at 1 mg/kg with maximum
dose 60 mg daily for treatment of AIN, to prevent development
of chronic renal impairment and ESRD. Ideally, steroids should
be rapidly weaned over the next 8–12 weeks to avoid the
recognized complications. A randomized controlled trial of ste-
roids in AIN would be required to provide stronger evidence for
this approach.
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